Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis

被引:91
作者
Hanwella, Raveen [1 ]
Senanayake, Madhri [1 ]
de Silva, Varuni [1 ]
机构
[1] Univ Colombo, Dept Psychol Med, Fac Med, Colombo, Sri Lanka
关键词
ONCE-A-DAY; DEFICIT/HYPERACTIVITY DISORDER; OPEN-LABEL; MULTICENTER; ADHD;
D O I
10.1186/1471-244X-11-176
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Psychostimulants and non stimulants are effective in the treatment of ADHD. Efficacy of both methylphenidate and atomoxetine has been established in placebo controlled trials. Direct comparison of efficacy is now possible due to availability of results from several head-to-head trials of these two medications. Methods: All published, randomized, open label or double blind trials, comparing efficacy of methylphenidate with atomoxetine, in treatment of ADHD in children, diagnosed using DSM-IV (TM) criteria were included. The outcome studied was ADHDRS-IVParent:Inv score. The standardized mean difference (SMD) was used as a measure of effect size. Results: Nine randomized trials comparing methylphenidate and atomoxetine, with a total of 2762 participants were included. Meta-analysis did not find a significant difference in efficacy between methylphenidate and atomoxetine (SMD = 0.09, 95% CI -0.08-0.26) (Z = 1.06, p = 0.29). Synthesis of data from eight trials found no significant difference in response rates (RR = 0.93 95% CI 0.76-1.14, p = 0.49). Sub group analysis showed a significant standardized mean difference favouring OROS methylphenidate (SMD = 0.32, 95% CI 0.12-0.53 (Z = 3.05, p < 0.002). Immediate release methylphenidate was not superior to atomoxetine (SMD = -0.04, 95% CI -0.19-0.12) (Z = 0.46, p = 0.64). Excluding open label trials did not significantly alter the effect size (SMD = 0.08, 95% CI -0.04-0.21) (Z = 1.27, p = 0.20). All-cause discontinuation was used as a measure of acceptability. There was no significant difference in all cause discontinuation between atomoxetine and methylphenidate (RR 1.22, 95% CI 0.87-1.71). There was significant heterogeneity among the studies (p = 0.002, I-2 = 67%). Subgroup analysis demonstrated the heterogeneity to be due to the open label trials (p = 0.001, I-2 = 81%). Conclusions: In general atomoxetine and methylphenidate have comparable efficacy and equal acceptability in treatment of ADHD in children and adolescents. However OROS methylphenidate is more effective than atomoxetine and may be considered as first line treatment in treatment of ADHD in children and adolescents.
引用
收藏
页数:8
相关论文
共 50 条
[41]   Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder [J].
Bedard, Anne-Claude V. ;
Stein, Mark A. ;
Halperin, Jeffrey M. ;
Krone, Beth ;
Rajwan, Estrella ;
Newcorn, Jeffrey H. .
JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY, 2015, 56 (01) :40-48
[42]   An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder [J].
Shang, Chi-Yung ;
Pan, Yi-Lei ;
Lin, Hsiang-Yuan ;
Huang, Lin-Wan ;
Gau, Susan Shur-Fen .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2015, 25 (07) :566-573
[43]   Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis [J].
Stuhec, Matej ;
Lukic, Petar ;
Locatelli, Igor .
ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) :121-133
[44]   Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder [J].
Ozbaran, Burcu ;
Kose, Sezen ;
Yuzuguldu, Onur ;
Atar, Burcu ;
Aydin, Cahide .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2015, 16 (08) :619-624
[45]   Therapeutic efficacy of probiotics for symptoms of attention-deficit hyperactivity disorder in children and adolescents: meta-analysis [J].
Liang, Shun-Chin ;
Sun, Cheuk-Kwan ;
Chang, Chih-Hua ;
Cheng, Yu-Shian ;
Tzang, Ruu-Fen ;
Chiu, Hsien-Jane ;
Wang, Ming Yu ;
Cheng, Ying-Chih ;
Hung, Kuo-Chuan .
BJPSYCH OPEN, 2024, 10 (01)
[46]   Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials [J].
Castells, Xavier ;
Cunill, Ruth ;
Capella, Dolors .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (03) :347-356
[47]   The Efficacy of Acupuncture Treatment for Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-Analysis [J].
Chen, Yi-Chen ;
Wu, Li-Kung ;
Lee, Ming-Shinn ;
Kung, Yen-Lun .
COMPLEMENTARY MEDICINE RESEARCH, 2021, 28 (04) :357-367
[48]   BMI Changes in Children and Adolescents with Attention Deficit Hyperactivity Disorder Before and After Treatment with Methylphenidate [J].
Kousha, Maryam ;
Dalili, Setila ;
Kiani, Seyyed Amir ;
Zare, Maryam ;
Karambin, Mohammad Mahdi ;
Heidarzadeh, Abtin ;
Koohmanaee, Shahin ;
Rad, Afagh Hassanzadeh .
IRANIAN JOURNAL OF PEDIATRICS, 2018, 28 (02)
[49]   Massage therapy for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents: A systematic review and meta-analysis [J].
Chen, Shu-Cheng ;
Yu, Branda Yee-Man ;
Suen, Lorna Kwai-Ping ;
Yu, Juan ;
Ho, Fiona Yan-Yee ;
Yang, Jun-Jun ;
Yeung, Wing-Fai .
COMPLEMENTARY THERAPIES IN MEDICINE, 2019, 42 :389-399
[50]   Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment [J].
Huss, Michael ;
Sikirica, Vanja ;
Hervas, Amaia ;
Newcorn, Jeffrey H. ;
Harpin, Valerie ;
Robertson, Brigitte .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 :1085-1101